French regulator allows Pharnext to omit phase I in Charcot-Marie-Tooth

Scrip   

French regulator allows Pharnext to omit phase I in Charcot-Marie-Tooth
Today
John Hodgson

The French Agency for Healthcare Product Safety (AFSSAPS) has authorised a Phase II clinical trial with the first multi-drug formulation (PXT3003 ) from the company's Pleotherapy technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A).